Prenetics Global Limited (PRE) Q3 Revenue Rose 228% YoY; Raises H2 EBITDA Loss Outlook
Prenetics reported Q3 2026 revenue of $64.1M, up 228% YoY, with a quarterly loss of $25.4M. The company raised its H2 EBITDA loss outlook to $30–35M, up from $8–12M, while reaffirming FY2026 revenue guidance of $220–230M and FY2027 IM8 revenue guidance of $400M or more.
How this was made

The 30-second read
Why it matters
The key trading variable is the step-up in expected H2 Adjusted EBITDA loss to $30–35M, which can pressure valuation multiples even as revenue guidance is reaffirmed.
Market read
Traders will likely focus on whether the higher spending implied by the loss outlook is consistent with sustained revenue growth and improving acquisition efficiency.
What to watch
The article does not provide customer-acquisition return metrics or cash burn details, so traders may overreact to EBITDA loss without confirming whether the spending is translating into durable revenue acceleration.
Background
Prenetics is reporting another quarter of rapid revenue growth while adjusting its second-half profitability outlook.
Ticker impact
Prenetics reported Q3 2026 revenue of $64.1M (+228% YoY) and guided H2 Adjusted EBITDA loss of $30–35M, versus $8–12M expected in August.
Likely mixed-to-negative near-term reaction as investors reprice the larger-than-expected loss trajectory despite reaffirmed revenue targets.
The article discloses both a strong top-line print and a clear, updated loss outlook for the second half, which typically drives valuation and risk sentiment more than revenue growth alone.
Market effects
Signals heightened spending and execution risk in consumer health diagnostics/healthtech models where acquisition costs can pressure EBITDA before scaling.
No specific regional market catalyst beyond the issuer’s own guidance.
Limited, company-specific guidance update with no stated cross-border policy or supply-chain shock.
Counterpoint
The wider H2 EBITDA loss may reflect deliberate investment to sustain the very high YoY revenue growth, which could improve future unit economics if customer-acquisition payback shortens.
Key entities
- companyPrenetics Global Limited
Reported Q3 2026 revenue growth and raised its expected H2 Adjusted EBITDA loss range while reaffirming FY2026 revenue guidance.


